BIO chair slams Trump’s HHS, calls to stop Russ­ian dis­in­for­ma­tion cam­paign on vac­cines

5 years ago
People
Pharma

What’s in a (drug) name? FDA to study how they af­fect ef­fi­ca­cy per­cep­tions

5 years ago
FDA+

Daphne Koller lines up $400M for a glob­al shop­ping spree to vault for­ward on AI drug dis­cov­ery

5 years ago
Financing
AI

Melin­ta Ther­a­peu­tics nabs FDA nod for more con­ve­nient re­work of an­tibi­ot­ic Or­bac­tiv, a for­mer Eli Lil­ly can­di­date

5 years ago
FDA+

Galec­to shelves high dose of IPF drug af­ter SAE im­bal­ance; Long­time Aveo part­ner hands back HER3 an­ti­body

5 years ago
News Briefing

Af­ter good news in sick­le cell, blue­bird bio fol­lows up with pos­i­tive long-term da­ta in Loren­zo’s Oil dis­ease

5 years ago
Cell/Gene Tx

Vivek Ra­maswamy's LNP de­liv­ery tech play Genevant scores $600M li­cens­ing deal from Take­da for nu­cle­ic acid ther­a­pies

5 years ago
People
Deals

Covid-19 roundup: Ger­many sus­pends As­traZeneca vac­cine as British drug­mak­er de­fends shot amid blood clot scare

5 years ago
Coronavirus

Gilead, Mer­ck put aside ri­val­ry to chal­lenge Glax­o­SmithK­line for long-act­ing HIV meds

5 years ago
Deals

Next-gen gene edit­ing up­start is grab­bing the brass ring with a $150M crossover play to back its bid on a cure for ...

5 years ago
Financing
Cell/Gene Tx

Ru­bius chief lays out the first hu­man da­ta on their lead red cell drug in a come­back play. And the stock sky­rock­ets

5 years ago
R&D

Roche drops $1.85B for Gen­Mark's test­ing tech as pan­dem­ic, an­tibi­ot­ic re­sis­tance threats loom

5 years ago
Deals

Backed by In­di­an biosim gi­ant Bio­con, bis­pecifics play­er Bicara de­buts with $40M and sol­id tu­mors on the radar

5 years ago
Financing
Startups

El­e­vate­Bio adds an­oth­er $525M to its war chest as it looks to build on next-gen man­u­fac­tur­ing 'base­cam­p'

5 years ago
Financing
Cell/Gene Tx

On a roll, Re­gen­eron and Sanofi boast pos­i­tive PhI­II OS re­sults in 'no­to­ri­ous­ly' tough can­cer

5 years ago
R&D
Pharma

With hopes for an­ti­bod­ies wan­ing, the NIH will test No­var­tis part­ner's nov­el an­tivi­ral in hos­pi­tal­ized Covid-19 ...

5 years ago
R&D
Coronavirus

Eli Lil­ly touts a 'con­stel­la­tion' of suc­cess­es with their PhII Alzheimer’s study — but dis­ap­point­ing fail­ures ...

5 years ago
Bioregnum
R&D

No­var­tis' wild card block­buster con­tender falls flat; Reg­u­la­to­ry reck­on­ing for check­point drugs looms; and more

5 years ago
Weekly

As­traZeneca ex­pects US vac­cine da­ta ‘soon’ — with 50M dos­es ready by the end of April

5 years ago
Coronavirus

Aveo teams with Bris­tol My­ers af­ter sur­prise FDA ap­proval; Cal­ciMed­ica lines up $21M raise to ad­vance Covid-19 ...

5 years ago
News Briefing

Prometheus and Long­board make the leap to Nas­daq with 9-fig­ure of­fer­ings and are joined by a Fal­con Edge-backed SPAC

5 years ago
Financing

Al­bert Bourla bagged $21M in year marked by gener­ics spin­off, colos­sal R&D ef­fort for Covid-19 vac­cine

5 years ago
People

With Kathy High on board, AskBio makes next lead­er­ship play and se­lects Bay­er's Gu­ru Ra­ma­murthy as fi­nance chief; ...

5 years ago
Peer Review

Lil­ly diss­es Am­gen and Mi­rati as it de­buts new KRAS mol­e­cule

5 years ago
Discovery
Pharma
First page Previous page 722723724725726727728 Next page Last page
A service from the Financial Times